Drug-eluting stents: results, promises and problems

Landau, 1994, Percutaneous transluminal coronary angioplasty, N. Engl. J. Med., 330, 981, 10.1056/NEJM199404073301407 Mintz, 1996, Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study, Circulation, 94, 35, 10.1161/01.CIR.94.1.35 Fischman, 1994, A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators, N. Engl. J. Med., 331, 496, 10.1056/NEJM199408253310802 Kiemeneij, 2001, Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial, J. Am. Coll. Cardiol., 37, 1598, 10.1016/S0735-1097(01)01207-4 Lowe, 2002, Coronary in-stent restenosis: current status and future strategies, J. Am. Coll. Cardiol., 39, 183, 10.1016/S0735-1097(01)01742-9 Hoffmann, 1996, Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study, Circulation, 94, 1247, 10.1161/01.CIR.94.6.1247 Grewe, 2000, Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen, J. Am. Coll. Cardiol., 35, 157, 10.1016/S0735-1097(99)00486-6 Farb, 1999, Pathology of acute and chronic coronary stenting in humans, Circulation, 99, 44, 10.1161/01.CIR.99.1.44 Kornowski, 1998, In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia, J. Am. Coll. Cardiol., 31, 224, 10.1016/S0735-1097(97)00450-6 Brasen, 2001, Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries, Arterioscler. Thromb. Vasc. Biol., 21, 1720, 10.1161/hq1101.098230 Kimura, 2002, Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries, Circulation, 105, 2986, 10.1161/01.CIR.0000019743.11941.3B Glover, 2002, Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation, Am. Heart J., 144, 702, 10.1016/S0002-8703(02)00145-X Chung, 2002, Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment, J. Am. Coll. Cardiol., 40, 2072, 10.1016/S0735-1097(02)02598-6 Kuroda, 2002, Intimal hyperplasia regression from 6 to 12 months after stenting, Am. J. Cardiol., 89, 869, 10.1016/S0002-9149(02)02205-1 Salame, 2001, Intracoronary radiation therapy, Eur. Heart J., 22, 629, 10.1053/euhj.2000.2338 Faxon, 2002, Systemic drug therapy for restenosis: “deja vu all over again”, Circulation, 106, 2296, 10.1161/01.CIR.0000038412.38399.D5 Versaci, 2002, Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study), J. Am. Coll. Cardiol., 40, 1935, 10.1016/S0735-1097(02)02562-7 Fujita, 2003, Sarpogrelate treatment reduces restenosis after coronary stenting, Am. Heart J., 145, E16, 10.1067/mhj.2003.176 Lincoff, 1994, Local drug delivery for the prevention of restenosis. Fact, fancy, and future, Circulation, 90, 2070, 10.1161/01.CIR.90.4.2070 Wohrle, 2001, Comparison of the heparin coated vs the uncoated Jostent—no influence on restenosis or clinical outcome, Eur. Heart J., 22, 1808, 10.1053/euhj.2001.2608 Lovich, 2001, Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel, J. Pharm. Sci., 90, 1324, 10.1002/jps.1085 Hwang, 2001, Physiological transport forces govern drug distribution for stent-based delivery, Circulation, 104, 600, 10.1161/hc3101.092214 van der Giessen, 1996, Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries, Circulation, 94, 1690, 10.1161/01.CIR.94.7.1690 Drachman, 2000, Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months, J. Am. Coll. Cardiol., 36, 2325, 10.1016/S0735-1097(00)01020-2 Suzuki, 2001, Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model, Circulation, 104, 1188, 10.1161/hc3601.093987 Lewis, 2002, Phosphorylcholine-coated stents, J. Long-Term Eff. Med. Implants, 12, 231, 10.1615/JLongTermEffMedImplants.v12.i4.20 Palmaz, 2002, Influence of stent design and material composition on procedure outcome, J. Vasc. Surg., 36, 1031, 10.1067/mva.2002.129113 Tamai, 2000, Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans, Circulation, 102, 399, 10.1161/01.CIR.102.4.399 Finkelstein, 2003, Local drug delivery via a coronary stent with programmable release pharmacokinetics, Circulation, 107, 777, 10.1161/01.CIR.0000050367.65079.71 Marx, 2001, Bench to bedside: the development of rapamycin and its application to stent restenosis, Circulation, 104, 852, 10.1161/01.CIR.104.8.852 Morice, 2002, A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N. Engl. J. Med., 346, 1773, 10.1056/NEJMoa012843 Moses, 2003, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery, N. Engl. J. Med., 349, 1315, 10.1056/NEJMoa035071 Schofer, 2003, Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS), Lancet, 362, 1093, 10.1016/S0140-6736(03)14462-5 Rowinsky, 1995, Paclitaxel (taxol), N. Engl. J. Med., 332, 1004, 10.1056/NEJM199504133321507 Gershlick, 2002, European evaLUation of pacliTaxel eluting Stent (ELUTES), Circulation, 105, E39 Park, 2003, A paclitaxel-eluting stent for the prevention of coronary restenosis, N. Engl. J. Med., 348, 1537, 10.1056/NEJMoa021007 Grube, 2003, TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions, Circulation, 107, 38, 10.1161/01.CIR.0000047700.58683.A1 Colombo, 2003, Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions, Circulation, 108, 788, 10.1161/01.CIR.0000086926.62288.A6 de La Fuente, 2001, Initial results of the Quanam drug eluting stent (QuaDS-QP-2) registry (BARDDS) in human subjects, Catheter. Cardiovasc. Interv., 53, 480, 10.1002/ccd.1207 Honda, 2001, Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system, Circulation, 104, 380, 10.1161/hc2901.094149 Kataoka, 2001, Prevention of restenosis by a new drug eluting stent: an intravascular ultrasound substudy of the SCORE trial, Circulation, 104, 3307 Liistro, 2001, Late acute thrombosis after paclitaxel eluting stent implantation, Heart, 86, 262, 10.1136/heart.86.3.262 Abizaid, 2003, First clinical experience with 17-estradiol-eluting BiodivYsio matrix LO stent to prevent restenosis in de-novo native coronary arteries: six-month clinical outcomes and angiographic follow-up from the EASTER trial, J. Am. College Cardiol., 41, 56A, 10.1016/S0735-1097(03)80241-3 Shirota, 2003, Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue, Biomaterials, 24, 2295, 10.1016/S0142-9612(03)00042-5 Kutryk, 2002, Progenitor cell capture for the accelerated endothelialization of endovascular devices, Am. J. Cardiol., 90, TCT180 Degertekin, 2003, Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience, J. Am. Coll. Cardiol., 41, 184, 10.1016/S0735-1097(02)02704-3 Liistro, 2002, First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome, Circulation, 105, 1883, 10.1161/01.CIR.0000016042.69606.61 Sousa, 2003, Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study, Circulation, 107, 24, 10.1161/01.CIR.0000047063.22006.41 Tanabe, 2003, TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation, Circulation, 107, 559, 10.1161/01.CIR.0000048184.96491.8A Virmani, 2003, Drug eluting stents: are human and animal studies comparable?, Heart, 89, 133, 10.1136/heart.89.2.133 2002, Long-term effects of stent-based delivery of sirolimus in the porcine model, Am. J. Cardiol., 90, TCT199 Babinska, 1998, Enhancement of human platelet aggregation and secretion induced by rapamycin, Nephrol. Dial. Transplant., 13, 3153, 10.1093/ndt/13.12.3153 Lemos, 2003, Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry, J. Am. Coll. Cardiol., 41, 2093, 10.1016/S0735-1097(03)00429-7 Lee, 2003, Safety and efficacy of sirolimus-eluting stent (cypher) in acute myocardial infarction: a substudy of the rapamycin-eluting stent evaluation at Rotterdam cardiology hospital (RESEARCH) study, J. Am. Coll. Cardiol., 41, 21A, 10.1016/S0735-1097(03)80088-8 FDA Public Health Web Notification: Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Coronary Stent. 29-10-2003. Curcio, 2004, Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis, Am. J. Physiol. Heart Circ. Physiol., 28b, 902, 10.1152/ajpheart.00130.2003 Lemos, 2003, Coronary restenosis after sirolimus-eluting stent implantation. Morphological description and mechanistic analysis from a consecutive series of cases, Circulation, 108, 257, 10.1161/01.CIR.0000083366.33686.11 Colombo, 2003, Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation, Circulation, 107, 2178, 10.1161/01.CIR.0000070592.04766.36 Cutlip, 2002, Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials, J. Am. Coll. Cardiol., 40, 2082, 10.1016/S0735-1097(02)02597-4 Morice, 1998, The MUST trial: acute results and six-month clinical follow-up, J. Invasive Cardiol., 10, 457 de Jaegere, 1998, Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study), Eur. Heart J., 19, 1214, 10.1053/euhj.1998.1012